Inactive Instrument

News Vifor Pharma AG SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT

Equities

VIFN

CH0364749348

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	23-05-02	CI
Court Cancels Public Shares of Vifor Pharma after Merger with CSL	22-12-14	MT
Cancellation of remaining publicly held registered shares of Vifor Pharma AG	22-12-14	BU
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	22-11-28	BU
Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	22-11-25	BU
Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	22-11-02	MT
Approval of extension of exemptions from SIX disclosure and publicity obligations	22-10-20	BU
Australia's CSL raises annual profit forecast on Swiss acquisition	22-10-16	RE
Global markets live: Darktrace, Intel, Twitter, Meta, Uber...	22-10-12
Vifor Pharma Gets Approval To Delist From Swiss Bourse	22-10-12	MT
Approval of delisting of Vifor Pharma AG's registered shares	22-10-12	BU
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	22-09-27	MT
Fitch Pulls Vifor Pharma's Rating After CSL Takeover	22-08-25	MT
Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	22-08-22	MT
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy	22-08-22	BU
Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	22-08-22	MT
VFMCRP announces U.S. Court upholds validity of Velphoro® patent	22-08-22	BU
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022	22-08-19	BU
VFMCRP - Tavneos (avacopan) recommended by England's NICE for the treatment of AAV (GPA/MPA)	22-08-18	AQ
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	22-08-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vifor Pharma AG SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT

Equities

VIFN

CH0364749348

Summary

Filters